A Study to Evaluate the Safety, Pharmacokinetics, and Anti-Tumor Activity of RO7589831 as Monotherapy and in Combination With Pembrolizumab in Participants With Advanced Solid Tumor
NCT 06004245 Brief Summary This is a first-in-human, Phase I, open-label, multicenter,…
Read more arrow_forward